Medically reviewed by Gagandeep Brar, MD Key Takeaways CMML is a rare form of leukemia that can cause extreme fatigue, easy ...

– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...

BOSTON, Dec. 9, 2024 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...

BOSTON, Dec. 2, 2024 /PRNewswire/ -- Solu Therapeutics ("Solu Therapeutics" or "Solu"), a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and ...

“Salarius is now fully compliant with all Nasdaq listing requirements, marking another critical step in our planned merger with Decoy Therapeutics,” said Mark J. Rosenblum, acting CEO and CFO of ...

Blood Cancer United, which was formerly known as the Leukemia & Lymphoma Society, has created a way for blood cancer patients ...

"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...

Funding to support clinical evaluation of STX-0712, drive additional pipeline programs, and target new applications of company's proprietary CyTAC™ and TicTAC™ platforms. Phase 1 trial of STX-0712 to ...

The Duke men’s basketball team and other participants took part in a one-mile dribble Saturday as part of the annual Dribble ...